Sign in
4

Changes in Ownership

Kalaris Therapeutics, Inc. Filed Acc 0001209191-23-056320

Chief Accounting Officer sold 403 shares at $1.63 ($657)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Hagen Brett R · Chief Accounting Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2023-11-17 Sale : show line 1 in the form 10b5-1 −403 $1.63 $657 125,835 D
Open-market sales · 403 sh · avg $1.63 · $657
Loading xslF345X05/doc4.xml…